1 day ago · Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over t...

2 days ago · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42 ...

13 hours ago · Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes the sell-off has created an attractive buying opportunity.

1 day ago · Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday.

20 hours ago · Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday.

1 day ago · The sell-off in Regeneron Pharmaceuticals presents an opportunity for investors to buy the stock on the cheap, according to Leerink Partners. Analyst David Risinger upgraded shares to outperform.

Jan 28, 2025 · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. As of January 28, 2025, the ...

1 day ago · Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $959.83, according to analysts polled by FactSet. ...

Jan 28, 2025 · On Tuesday, Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ: REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating.